Second brazilian consensus on the treatment of advanced prostate cancer: a SBOC-SBU-SBRT panel review
AUTOR(ES)
Sasse, Andre Deeke
FONTE
Int. braz j urol.
DATA DE PUBLICAÇÃO
27/06/2019
RESUMO
ABSTRACT Prostate cancer is the second most common cancer and the fifth leading cause of cancer deaths. In Brazil, it is likewise the second most common cancer among men, second only to non-melanoma skin cancers. The aim of this consensus is to align different opinions and interpretations of the medical literature in a practical and patient-oriented approach. The first Brazilian Consensus on the Treatment of Advanced Prostate Cancer was published in 2017, with the goal of reducing the heterogeneity of therapeutic conduct in Brazilian patients with metastatic prostate cancer. We acknowledge that in Brazil the incorporation of different technologies is a big challenge, especially in the Sistema Único de Saúde (SUS), which allows for the disparity in the options available to patients treated in different institutions. In order to update the recommendations and to make them objective and easily accessible, once more a panel of specialists was formed in order to discuss and elaborate a new Brazilian Consensus on Advanced Prostate Cancer. This Consensus was written through a joint initiative of the Brazilian Society of Clinical Oncology (SBOC) and the Brazilian Society of Urology (SBU) to support the clinical decisions of physicians and other health professionals involved in the care of patients with prostate cancer.
Documentos Relacionados
- First brazilian consensus of advanced prostate cancer: recommendations for clinical practice
- Available evidence on HIFU for focal treatment of prostate cancer: a systematic review
- National Consensus on Non-metastatic Castration-Resistant Prostate Cancer: more than just a snapshot
- Prostate cancer as a first and second cancer: effect of family history
- Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience